MGNX (Macrogenics) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


MGNX Macrogenics Inc MGNX
47 GF Score
Price $4.73
GF Value $4.08
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Macrogenics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Macrogenics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

MGNX vs CNTX, TARA, ACIU: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Macrogenics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Macrogenics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Macrogenics's Margin of Safety % (DCF Earnings Based) falls into.


MGNX
47GF Score
Macrogenics Inc MGNX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Macrogenics (MGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of $4.73 is trading 15.9% above its estimated GF Value™ of $4.08. GuruFocus considers Macrogenics to be Modestly Overvalued.

Key valuation signals for MGNX:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $4.08 vs. price of $4.73 (15.9% above fair value)
  • GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the MGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Other Exchanges M55:Germany
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
47GF Score

Get the complete analysis for MGNX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.73
Price
$4.08
GF Value